Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents

Journal Article · · Scientific Reports
 [1];  [1];  [1];  [1];  [1];  [2]
  1. Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States). Chemical Sciences Division
  2. Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States). Chemical Sciences Division; Univ. of California, Berkeley, CA (United States). Dept. of Nuclear Engineering
+ Show Author Affiliations

Several MRI contrast agent clinical formulations are now known to leave deposits of the heavy metal gadolinium in the brain, bones, and other organs of patients. This persistent biological accumulation of gadolinium has been recently recognized as a deleterious outcome in patients administered Gd-based contrast agents (GBCAs) for MRI, prompting the European Medicines Agency to recommend discontinuing the use of over half of the GBCAs currently approved for clinical applications. Here, to address this problem, we find that the orally-available metal decorporation agent 3,4,3-LI(1,2-HOPO) demonstrates superior efficacy at chelating and removing Gd from the body compared to diethylenetriaminepentaacetic acid, a ligand commonly used in the United States in the GBCA Gadopentetate (Magnevist). Using the radiotracer 153Gd to obtain precise biodistribution data, the results herein, supported by speciation simulations, suggest that the prophylactic or post-hoc therapeutic use of 3,4,3-LI(1,2-HOPO) may provide a means to mitigate Gd retention in patients requiring contrast-enhanced MRI.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1433132
Journal Information:
Scientific Reports, Journal Name: Scientific Reports Journal Issue: 1 Vol. 8; ISSN 2045-2322
Publisher:
Nature Publishing GroupCopyright Statement
Country of Publication:
United States
Language:
English

References (34)

Biodistribution of the Multidentate Hydroxypyridinonate Ligand [ 14 C]-3,4,3-LI(1,2-HOPO), a Potent Actinide Decorporation Agent : BIODISTRIBUTION OF 3,4,3-LI(1,2-HOPO) journal April 2015
Primer on gadolinium chemistry journal December 2009
Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms journal April 2016
From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents journal April 2017
Gadolinium toxicity: Iron and ferroportin as central targets journal December 2016
Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience journal December 2016
A kinetic investigation of the lanthanide DOTA chelates. Stability and rates of formation and of dissociation of a macrocyclic gadolinium(III) polyaza polycarboxylic MRI contrast agent journal March 1992
Using the Antenna Effect as a Spectroscopic Tool: Photophysics and Solution Thermodynamics of the Model Luminescent Hydroxypyridonate Complex [Eu III (3,4,3-LI(1,2-HOPO))] − journal December 2009
Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands journal January 1988
3,4,3-LI(1,2-HOPO): In vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation journal January 2011
Receptor recognition of transferrin bound to lanthanides and actinides: a discriminating step in cellular acquisition of f-block metals journal January 2013
Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo : comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO journal January 2000
In Vivo Chelation of Am(III), Pu(IV), Np(V), and U(VI) in Mice by TREN-(Me-3,2-HOPO) journal May 1994
Gross Composition and Plasma and Extracellular Water Volumes of Tissues of a Reference Mouse journal January 1992
Lauriston s. Taylor Lecture: the Quest for Therapeutic Actinide Chelators journal January 2008
Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy journal January 2006
Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion journal January 2016
Gadolinium Retention in the Dentate Nucleus and Globus Pallidus Is Dependent on the Class of Contrast Agent journal June 2015
Dose-Dependent Efficacy and Safety Toxicology of Hydroxypyridinonate Actinide Decorporation Agents in Rodents: Towards a Safe and Effective Human Dosing Regimen journal February 2013
Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging journal August 2006
Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy journal December 2010
238 Pu elimination profiles after delayed treatment with 3,4,3LI(1,2HOPO) in female and male Swiss-Webster mice journal August 2014
Environmental Fate of EDTA and DTPA book January 1997
Gadolinium deposition in the brain: Lessons learned from other metals known to cross the blood–brain barrier journal December 2016
Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review journal March 2011
In Vivo Chelation of Am(III), Pu(IV), Np(V), and U(VI) in Mice by TREN-(Me-3,2-HOPO) journal May 1994
Lauriston s. Taylor Lecture: the Quest for Therapeutic Actinide Chelators journal January 2008
Biomimetic Actinide Chelators: an Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-Li(1,2-Hopo) and 5-Lio(Me-3,2-Hopo) journal January 2010
Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion journal January 2016
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C journal January 2008
Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy journal July 2015
Dose-Dependent Efficacy and Safety Toxicology of Hydroxypyridinonate Actinide Decorporation Agents in Rodents: Towards a Safe and Effective Human Dosing Regimen journal February 2013
Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging journal August 2006
Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned journal February 2007

Cited By (11)

Fibromyalgia associated with repeated gadolinium contrast-enhanced MRI examinations journal May 2020
Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model journal January 2019
Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs journal February 2019
Recent Advances of Bioresponsive Nano-Sized Contrast Agents for Ultra-High-Field Magnetic Resonance Imaging journal March 2020
Evaluating the Patient with Reported Gadolinium-Associated Illness journal November 2018
High-throughput screening for discovery of benchtop separations systems for selected rare earth elements journal January 2020
Lanthanum chloride induces autophagy in rat hippocampus through ROS-mediated JNK and AKT/mTOR signaling pathways journal January 2019
Inducing selectivity and chirality in group IV metal coordination with high-denticity hydroxypyridinones journal January 2019
Combinatorial design of multimeric chelating peptoids for selective metal coordination journal January 2019
Gadolinium-based contrast agents – what is the evidence for ‘gadolinium deposition disease’ and the use of chelation therapy? journal October 2019
Ex vivo quantification of lanthanum and gadolinium in post-mortem human tibiae with estimated barium and iodine concentrations using K x-ray fluorescence journal August 2019

Similar Records

Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis
Journal Article · Sun Jan 31 23:00:00 EST 2010 · Nanomedicine, 6(1):1-8 · OSTI ID:1015281
From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents
Journal Article · Thu Mar 31 00:00:00 EDT 2016 · Chemico-Biological Interactions · OSTI ID:1458488
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients
Journal Article · Wed Aug 01 00:00:00 EDT 1984 · AJR, Am. J. Roentgenol.; (United States) · OSTI ID:6604082

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
60 APPLIED LIFE SCIENCES